Genuinely effective obesity drugs, as GLP-1s appear to be, should have a positive impact on the bottom line of US health insurers like Cigna (CI), United Healthcare (UNH), Humana (HUM) and Centene (CNC) in the long term while harming companies paying for these very expensive and likely to be in-demand medications like Insperity (NSP) and Robert Half (RHI)
it is banned at all times, in and out of competition, for athletes subject to anti-doping codes, and is not classified under S2 (Peptide Hormones, Growth Factors, and Related Substances), which is reserved for specifically defined peptide hormones and growth factors such as hGH and EPO
Stay hydrated, as even mild dehydration can affect hormone signals
This observation coincides with in vitro findings by Rebouche et al
Challenges regarding GLP-1 agonists include anti-fibrosis, long-term tolerability, and regaining weight
The most commonly prescribed medications in this category include semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound), which are FDA-approved specifically for chronic weight management